Sanofi opens R&D center in China

Sanofi-Aventis has opened its first R&D center in China, which it hopes will allow it to tap the burgeoning Chinese pharmaceuticals market. The French drugmaker is also pursuing R&D activities in Russia, South Korea and India as part of its ongoing strategy to expand in biologics, generics and emerging markets. R&D chief Marc Cluzel says in a statement that the new R&D center will help Sanofi develop therapies specifically for the Chinese population.

"We hope to become the first multinational drug company that completes truly home-grown research activities and will cooperate with local partners," said Thomas Kelly, VP of Sanofi's China operations, according to the Shanghai Daily.

- read the report on Sanofi

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.